Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications

Pathology and Oncology Research

Volumn 6, Issue 3, 2000, Pages 163-174

  Cohen, S A ^a   Trikha, M ^a   Mascelli, M A ^a  

^a CENTOCOR INC   (United States)

Author keywords

Abciximab; Angiogenesis; Cardiocascular disease; ReoPro ; Tumor metastasis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; INTEGRIN RECEPTOR; MONOCLONAL ANTIBODY LM 609; RETEPLASE; STREPTOKINASE; THROMBOCYTE RECEPTOR; TICLOPIDINE; VASCULOTROPIN;

ANGIOGENESIS; CANCER; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRUG SAFETY; ENDOTHELIUM CELL; HEART INFARCTION; HUMAN; METASTASIS INHIBITION; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR DISEASE; REVIEW; THROMBOCYTE; THROMBOSIS; TUMOR CELL; TUMOR GROWTH; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE;

EID: 0033646764     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03032368     Document Type: Review

References (107)

1. Intra myocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death
2. The role of platelets in arterial thrombosis and the rationale for blockade of platelet IIb/IIIa receptors as anti-thrombotic therapy
3. The International Stroke Trial (IST): A randomized trial of aspirin, subcutaneous heparin, both or neither among 19,435 patients with acute ischemic stroke
4. Randomized placebo-controlled trial of early aspirin use in 20,000 patients with subacute ischemic stroke
5. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated stents
6. Laboratory markers of platelet activation and their clinical significance
7. Fundamental of coagulation and glycoprotein IIb/IIIa receptor inhibition
8. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
9. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
10. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
11. Randomised placebo controlled trial of abciximab before, during and after coronary intervention in refractory unstable angina: The CAPTURE study
12. Randomised placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb-IIIa blockade
13. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents
14. Preclinical development of c7E3 Fab; a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GP IIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans
15. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
16. The pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade
17. Sustained suppression of ischemic complications of coronary intervention by platelet GPIIb/IIIa blockade with abciximab. One year outcome of the EPILOG trial
18. 3 blockade with percutaneous coronary intervention
19. 3 integrins
20. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthemia in Israel
21. A monoclonal antibody reacting with distinct adhesion molecules defines a transition in the functional state of the receptor CD11b/CD18 (Mac-1)
22. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1
23. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets
24. Molecular determinants of angiogenesis in cancer metastasis
25. New developments in angiogenesis: A major mechanism for tumor growth and target for therapy
26. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
27. Novel small molecule v integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors
28. 3-specific humanized mAb
29. Suppression of p53 activity and p21WAF1/CIPI expression by vascular cell integrin alphaVbeta 3 during angiogenesis
30. 3
31. 3: A new prognostic indicator in breast cancer
32. 3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy
33. 3
34. Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab; ReoPro(TM))
35. Inhibition of metastases by anticoagulants
36. Adhesion molecules and tumor metastasis: An update
37. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and Von Willebrand factor on tumor adhesion in vitro and metastasis in vivo
38. 3 in tumor-cell-induced platelet aggregation
39. 3 and tumor-cell-induced platelet aggregation
40. Inhibition of TPA and 12(S)-HETE-stimulated tumor cell adhesion by prostacyclin and its stable analogs: Rationale for their antimetastatic effects
41. Blockade of GPIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis
42. Involvement of platelets in tumour angiogenesis?
43. 111indium-labeled human platelets
44. Binding specificity and associated effects of platelet GPIIb/IIIa inhibitors
45. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets
46. In vitro release of vascular endothelial growth factor during platelet aggregation
47. Integrin expression in melanoma predicts subsequent metastasis
48. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma
49. Adenoviral gene transfer of 3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma
50. 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen
51. Involvement of integrin v gene expression in human melanoma tumorigenicity
52. 3 promotes M21 melanoma growth in human skin by regulating tumor cell survival
53. Immunoreactivity of glycoprotein IIb is present in metastasized but not in non-metastasized primary malignant melanoma
54. Characterization of tumor-induced platelet aggregation: The role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells
55. Autocrine motility factor signals integrin-mediated metastatic melanoma cell adhesion and invasion
56. Ectopic expression of platelet integrin IIb3 in tumor cells from various species and histological origin
57. The high affinity IIb3 integrin is involved in invasion of human melanoma cells
58. Human prostate carcinoma cells express functional IIb3 integrin
59. The intracellular polymerization of sickle hemoglobin and its relevance to sickle cell disease
60. Chromosomal localization of the human globin gene to chromosome 11 in somatic cell hybrids
61. The pathophysiology of vascular obstruction in the sickle syndromes
62. Genetics of red cells and susceptibility to malaria
63. Newborn screening for sickle cell disease: Effect on mortality
64. The natural history of sickle cell disease
65. Circulating activated endothelial cells in sickle cell anemia
66. Integrin alpha 4 beta I and glycoprotein IV (CD36) are expressed on circulating reticuloxytes in sickle cell anemia
67. Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells
68. Sickle reticulocytes adhere to VCAM-1
69. Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red cell adherence to endothelium: Potential role in sickle cell disease
70. Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: A potential role for platelet activation in sickle cell vascular occlusion
71. Adhesion of sickle cells to vascular endothelium is critically dependent on changes in density and shape of cells
72. Unusually large von Willebrand factor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow
73. 3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet activating factor
74. Platelet-activating factor in plasma of patients with sickle cell disease in steady state
75. Platelet-activating factor secreted by DDAVP-treated monocytes mediates von Willebrand factor release from endothelial cells
76. Platelet-erythrocyte adhesion in sickle cell disease
77. Platelet activation during crisis in sickle cell anemia patients
78. Survival and recurrence following stroke. The Framingham study
79. Clinical assessment of stroke
80. Epidemiology of stroke
81. The Greater Cincinnati/Northern Kentucky Stroke Study: Preliminary first-ever and total incidence rates of stroke among blacks
82. Epidemiologic profile of long-term stroke disability: The Framingham study
83. Anti-thrombotic therapy in acute ischemic stroke: An overview of the completed randomized trials
84. Lifetime cost of stroke in the United States
85. Incidence rates of stroke in the eighties: The end of the decline in stroke?
86. Tissue plasminogen activator for acute ischemic stroke
87. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke
88. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study
89. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators
90. Thrombolytic therapy with streptokinase in acute ischemic stroke
91. Randomised controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischemic stroke
92. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
93. Enhanced early reperfusion at 60 minutes with low-does retaplase combined with full-dose abciximab in acute myocardial infarction: Preliminary results from the GUSTO-4 pilot (SPEED) dose-ranging trial
94. Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial
95. The effect of peptides and monoclonal antibodies that bind to glycoprotein IIb/IIIa complex on the development of clot tension
96. Factor XIIIa binding to activated platelets is mediated through the activation of glycoprotein IIb-IIIa
97. Preliminary safety report of a randomized, double-blind dose escalation trial of abciximab (ReoPro) in acute ischemic stroke
98. Does abciximab reduce complications of cerebral vascular stenting in high risk sesions?
99. A comparison of retaplase with alteplase for acute myocardial infarction
100. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction
101. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
102. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 fab after thrombolytic therapy: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study
103. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: Results of a randomized, placebo-controlled, dose-ranging trial
104. Randomized, placebo-controlled study of lamifiban with thrombolytic therapy for the treatment of acute myocardial infarction: Rationale and design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) study
105. Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase and alteplase) during acite myoccardial infarction (results from the GUSTO-III trial)
106. Optimizing the percutaneous interventional oucomes for patients with diabetes mellitis: Results of the EPISTENT diabetic substudy